Optimizerx CORP Form 4 insider transactions

OptimizeRx Chief Operating Officer Brendan W. Merrell reported the disposition of 289 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Chief Business Officer Andrew J. D'Silva disposed of 703 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx's Chief Product & Tech Officer, Doug Besch, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx Chief Operating Officer Brendan W. Merrell disposed of 712 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Chief Business Officer Andrew J. D'Silva disposed of 868 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx Chief Operating Officer Brendan W. Merrell reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.

OptimizeRx Chief Business Officer Andrew J. D'Silva disposed of shares to cover tax withholding obligations on October 1 and October 3, 2025.

OptimizeRx Chief Commercial Officer Theresa Greco disposed of 1,693 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx CEO Stephen L. Silvestro converted restricted stock units into common shares and sold a portion to cover tax obligations.

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, converted restricted stock units into common stock, increasing his direct beneficial ownership.

OptimizeRx Chief Product & Tech Officer Doug Besch converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

OptimizeRx's Chief Business Officer, Andrew J. D'Silva, received a grant of 10,417 restricted stock units and 23,437 stock options.

OptimizeRx Director Patrick D. Spangler sold 11,120 shares of common stock for a weighted average price of $17.49 per share.

OptimizeRx CEO Stephen L. Silvestro received significant equity grants, including restricted stock units and stock options, as part of a pre-planned transaction.

OptimizeRx's Chief Legal & Admin Officer, Marion Odence-Ford, was granted 15,625 restricted stock units and 35,156 stock options.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, was granted 15,625 restricted stock units and options for 35,156 shares of common stock.

OptimizeRx Chief Commercial Officer Theresa Greco received 15,625 restricted stock units and 35,156 stock options as part of her compensation.

OptimizeRx's Chief Product & Technology Officer, Doug Besch, was granted restricted stock units and stock options.

OptimizeRx Corporation's Director, Cathy Klema, was granted 9,868 restricted stock units (RSUs) on June 11, 2025, as part of her compensation, aligning her interests with shareholders.

OptimizeRx Corp. Director James Paul Lang was granted 9,868 restricted stock units, increasing his beneficial ownership to 399,320 shares.

OptimizeRx Corp. Director Patrick D. Spangler was granted 9,868 restricted stock units, increasing his direct beneficial ownership to 55,335 shares.

OptimizeRx Corporation's Director, Ellen O'Connor Vos, was granted 9,868 restricted stock units (RSUs) on June 11, 2025, as part of her compensation.

OptimizeRx Corp. Director Gregory D. Wasson was granted 9,868 restricted stock units, aligning his interests with shareholders and increasing his beneficial ownership to 57,183 shares.

Theresa Greco, Chief Commercial Officer of OptimizeRx Corp, reports the acquisition of restricted stock units and stock options.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the acquisition of restricted stock units and stock options.

Director James Paul Lang purchased 321,408 shares of OptimizeRx Corp (OPRX) at a weighted average price of $7.6033 on March 14, 2025.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting of restricted stock units and subsequent tax withholding.

Marion Odence-Ford, Chief Legal Officer & CHRO of OptimizeRx Corp, reports the vesting and subsequent tax withholding of restricted stock units.

OptimizeRx CEO William Febbo disposed of 401 shares of common stock on February 14, 2025, to satisfy tax withholding obligations.